BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19121195)

  • 1. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval.
    Cid J; Ramiro L; Escoda L; Llorente A
    Vox Sang; 2009 Jan; 96(1):29-33. PubMed ID: 19121195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
    Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
    Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
    Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
    Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation.
    Dijkstra-Tiekstra MJ; van de Watering LM; Rondeel JM; Slomp J; de Wildt-Eggen J
    Transfus Med; 2014 Apr; 24(2):99-104. PubMed ID: 24506143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
    Diedrich B; Ringdén O; Watz E; Shanwell A
    Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of high-yield thrombocytapheresis on the quality of platelet products.
    Julmy F; Ammann RA; Mansouri Taleghani B; Fontana S; Hirt A; Leibundgut K
    Transfusion; 2008 Mar; 48(3):442-50. PubMed ID: 18067508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated preparation of platelet concentrates from pooled buffy coats using the Gambro OrbiSac system.
    Gulliksson H; Sjödin A; Sandgren P; Vesterinen M; Larsson S; Diedrich B
    Transfus Apher Sci; 2003 Aug; 29(1):11-2. PubMed ID: 12877886
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats.
    Klüter H; Dörges L; Maass E; Wagner T; Bartels H; Kirchner H
    Ann Hematol; 1996 Aug; 73(2):85-9. PubMed ID: 8774617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience.
    Gurevich-Shapiro A; Tzadok S; Rosenberg A; Inbal A; Bar-Natan M; Wolach O; Raanani P
    Acta Haematol; 2017; 137(4):183-190. PubMed ID: 28419992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet concentrates from buffy coats: improved conditions for preparation and evaluation in routine clinical use.
    Rebulla P; Bertolini F; Porretti L; Marangoni F; Smacchia C; Marconi M; Riccardi D; Sirelson V; Pappalettera M; Sirchia G
    Transfus Sci; 1993 Jan; 14(1):41-6. PubMed ID: 10148312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
    Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
    Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer.
    Pedrazzoli P; Perotti C; Noris P; Da Prada GA; Zibera C; Battaglia M; Gibelli N; Preti P; Pavesi L; Torretta L; Balduini CL; Salvaneschi L; Robustelli della Cuna G
    Haematologica; 1998 Aug; 83(8):718-23. PubMed ID: 9793256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, immunologic, and technical factors affecting recovery of platelet count after platelet transfusion.
    Inverardi D; Bocchio C; Rossi L; Mazzucco L; De Paoli L; Borzini P
    Haematologica; 2002 Aug; 87(8):893-4. PubMed ID: 12161372
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical factors influencing corrected count increment.
    Shastry S; Chaudhary R
    Transfus Apher Sci; 2012 Dec; 47(3):327-30. PubMed ID: 22705296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
    Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
    Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
    Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
    Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.